| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC1595 | Cumyl-pica | Agonist for the cannabinoid receptors, with Ki values of 59.21 nM at CB1 and 136.38 nM at CB2 and EC50 values of 11.98 nM at CB1 and 16.2 nM at CB2 |
|
| DCC1596 | Cuprizone | Inducer of demyelination and motor dysfunction via upregulation of IGF-1 |
|
| DCC1597 | Cv21/jr95 | Potent anti-cancer agent |
|
| DCC1598 | Cvk-003 | Novel dual PXR and AhR agonist |
|
| DCC1599 | Cvk-021 | Novel potent pregnane X Receptor (PXR) agonist |
|
| DCC1600 | Cvm-04-70 | Inhibitor of PIM, suppressing cyclin-Dependent Kinase 2 (CDK2) |
|
| DCC1601 | Cvm-05-002 | Novel potent and selective inhibitor of PI5P4Ks |
|
| DCC1602 | Cvs-1123 | Direct thrombin inhibitor, preventing occlusive arterial and venous thrombosis in a canine model of vascular injury |
|
| DCC1603 | Cvs-1578 | Potent serine protease inhibitor, targeting the S 2 S 3 thrombin and FXa subsites |
|
| DCC1604 | Cwhm-1552 | Novel orally efficacious antimalarial agent against P. falciparum 3D7 ( IC50: 51 nM) |
|
| DCC1605 | Cwhm-505 | Potent antimalarial agent against Plasmodium falciparum 3D7 |
|
| DCC1606 | Cwhm-505 Hydrochloride | Potent antimalarial agent against Plasmodium falciparum 3D7 |
|
| DCC1607 | Cwp231904 | Novel Wnt/β-Catenin Inhibitor, Preferentially Inhibiting the Growth of Breast Cancer Stem-like Cells |
|
| DCC1608 | Cx08005 | Novel potent and substrate-competitive PTP1B and TCPTP dual inhibitor |
|
| DCC1609 | Moxilubant Maleate | Potent LTB4 receptor antagonist |
|
| DCC1610 | Cx1739 | Novel low-impact ampakine that can safely activate AMPA receptors without causing excito-neurotoxicity, rapidly crossing the blood-brain barrier (T max = 2 min), protecting against respiratory depression |
|
| DCC1611 | Cx4338 | Novel inhibitor of CXCL8-mediated chemotaxis through selective regulation of CXCR2-mediated signaling |
|
| DCC1612 | Cx-659s | Nonsteroidal dermatologic and anti-inflammatory agent, blocking the MEK1/2-Erk1/2 pathway, inhibiting chronic contact hypersensitivity responses (CHRs) and the rebound phenomenon following withdrawal of corticosteroid therapy without immunosuppression |
|
| DCC1613 | Cxcr2 Antagonist 3e | Novel potent CXCR2 antagonist |
|
| DCC1614 | Cxcr2-in-c5 | Novel CXCR2 selective antagonist with a low CXCR1 antagonism preference |
|
| DCC1615 | Cy 208-243 | Selective D1 agonist with anti-Parkinsonian activity |
|
| DCC1616 | Cyanabactin | Novel ABA receptor agonist, preferentially activating Pyrabactin Resistance 1 (PYR1) with low nanomolar potency |
|
| DCC1617 | cyanonilutamide | Androgen receptor (AR) antagonist, inhibiting AR function in castrate-resistant prostate cancer (CRPC) |
|
| DCC1618 | Cyanotryptophan Featured | Blue fluorescent amino acid, exhibiting blue fluorescence (λ max ~ 405 nm) with a high quantum yield and long lifetime |
|
| DCC1619 | Cybluc | Novel Effective Aminoluciferin Derivative for Deep Bioluminescence Imaging |
|
| DCC1620 | Cyclomarin A | Natural antibacterial peptide, activating the AAA+ protease ClpC/ClpP, causing cell death by uncontrolled protein degradation |
|
| DCC1621 | Cyclopeptide 66 | Novel PD-1/PD-L1 inhibitor, binding two PD-L1 and efficiently block the PD-1/PD-L1 interaction |
|
| DCC1622 | Cyclophostin | Natural irreversible inhibitor of acetylcholinesterase (AChE) |
|
| DCC1623 | Cyclorasin B4-27 | Novel bicyclic peptidyl pan-Ras inhibitor, binding selectively to the GTP-bound forms of wild-type and mutant Ras isoforms (K D = 21 nM for KRasG12V-GppNHp) and being highly cell-permeable and metabolically stable (serum t1/2 > 24 h) |
|
| DCC1624 | Cyclo-sgwif(4-cl)wav | Novel Cyclic Peptide Inhibitor of the p6/UEV Protein-Protein Interaction, disrupting the p6/UEV interaction with an IC50 of 6.17 ± 0.24 μM by binding to UEV with a Kd of 11.9 ± 2.8 μM. |
|
